Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02387840 : Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
AgesMin: N/A Max: 35 Years
Inclusion Criteria:

- Subjects undergoing MRI evaluation of the brain

- NF1 status will be determined by clinical exam or genetic testing

- NF1-associated Optic Pathway Glioma (OPG) will be defined as radiographic evidence of
glioma along the optic nerve, chiasm, tract or radiation in a child with NF1

- Untreated low grade gliomas will be imaging-defined gliomas that have not yet been
exposed to radiation or systemic chemotherapy. Those exposed to therapy will have had
radiation and/or systemic chemotherapy more than 1 month prior to scans

Exclusion Criteria:

- History of mental retardation unrelated to brain tumor

- Presence of a genetic disorder other than NF1 that effects cognition or is associated
with MR imaging abnormalities (e.g. tuberous sclerosis)

- History of cerebrovascular accident (stroke)

- Birth weight below five pounds, premature birth prior to 36 weeks of gestation, or
ischemic episode at birth

- Major psychiatric diagnosis prior to neuro-oncological diagnosis
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557